Skip to Content

Label Changes for:

Miacalcin (calcitonin-salmon) nasal spray

October 2009

Changes have been made to the PRECAUTIONS and ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2009


Drug Interactions
  • Concomitant use of calcitonin and lithium may lead to a reduction in plasma lithium concentrations due to increased urinary clearance of lithium. The dose of lithium may need to be adjusted.


Immune system disorders
  • Hypersensitivity, anaphylaxis and anaphylactic shock